Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees.
The incidence and types of adverse reactions to rifampicin (in combination with isoniazid, pyrazinamide, and ethambutol) have been studied in 86 South-East Asian refugees treated for tuberculosis in Australia. Most patients received daily therapy initially (mean 3.5 months) followed by supervised thrice-weekly treatment (mean 4.6 months). Minor adverse reactions occurred with similar frequencies during daily (5%) and intermittent (5%) treatment but in no case was modification of rifampicin dosage required. Withdrawal of pyrazinamide was necessary in two patients (2.3%) with clinical hepatitis.